OGENHIGH SIGNALFINANCIAL10-K

OGEN executed a reverse stock split reducing outstanding shares from 21.5M to 4.3M while dramatically improving its balance sheet with stockholders' equity surging from negative $212K to positive $8.3M.

The reverse stock split (approximately 5:1 ratio) combined with the massive equity improvement suggests OGEN likely raised significant capital, possibly to meet exchange listing requirements. The transformation from negative to strongly positive stockholders' equity indicates successful fundraising that has substantially strengthened the company's financial position.

Comparing 2026-03-16 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

OGEN's financial position improved dramatically across all key metrics, with total assets growing 584% to $10.1M and cash increasing 409% to $4.4M, while stockholders' equity swung from negative $212K to positive $8.3M. Operating losses improved 11% to $9.4M and R&D expenses declined 42% to $2.4M, suggesting more disciplined spending. The overall picture signals a successful capital raise that has transformed the company from a financially distressed position to one with substantial liquidity and a clean balance sheet.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+4008.4%
-$212K$8.3M

Equity base grew 4008.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+583.7%
$1.5M$10.1M

Asset base grew 583.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+583.7%
$1.5M$10.1M

Current assets grew 583.7% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+408.7%
$865K$4.4M

Cash position surged 408.7% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
+190.6%
$44K$128K

Capital expenditure jumped 190.6% — major investment cycle underway; assess returns on deployment.

Interest Expense
P&L
+102.5%
$15K$31K

Interest expense surged 102.5% — significant debt increase or rising rates materially impacting earnings.

R&D Expense
P&L
-41.8%
$4.1M$2.4M

R&D spending cut 41.8% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
+12.6%
$1.6M$1.8M

Current liabilities rose 12.6% — increased short-term obligations, watch current ratio.

Operating Income
P&L
+11.3%
-$10.6M-$9.4M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-14
ADDED
As of March 13, 2026, there were 4,336,029 shares of the registrant s Common stock outstanding.
All share and per share amounts in these consolidated financial statements and related footnotes have been retroactively adjusted to reflect the reverse stock split for all periods presented in the accompanying financial statements, unless otherwise indicated (the Reverse Stock Split ).
Overview We are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases.
The Company is currently focused on advancing the development and commercialization of its lead product candidate, ONP-002.
Our lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and we believe it can cross the blood-brain barrier with the goal of rapidly eliminating swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
+7 more — sign up free →
REMOVED
As of March 10, 2025, there were 21,475,289 shares of the registrant s Common stock outstanding.
Overview We are a development-stage company dedicated to the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases.
Our lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and is designed to cross the blood-brain barrier with the goal of rapidly reducing swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
Our ONP-002 Neurology Asset for Brain Related Illness and Injury Following our December 2023 acquisition of certain assets from Odyssey Health, Inc.
( Odyssey ) related to the segment of Odyssey s business focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets ) our lead product and focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury ( mTBI or Concussion ).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →